Chennupalle Nageswara Reddy, Puthalapattu Reddy Prasad, Neelam Yugandhar Sreedhar


Zinecard is used to prevent a toxic effect to heart caused by certain medicines that are used to treat cancer.  Zinecard  is also  used  to  treat  tissue  damage  caused  by  the  leakage  of certain  medicines  that  are  used  to  treat  cancer.  Differential pulse  polarographic  method   developed  for  the  quantitative determination  of  zinecard  gives  a  peak  at  -0.32  V  at  DME. From  the  structural  point  of  view  zinecard  contains  a  >C=Omoiety  which  can  be  electrochemically  reduced  at  universal buffer  (pH  4.0).  Millicoulometric  experiment  is  performed successfully  in  estimating  the  number  of  electrons  and  proton to  understand  reduction  mechanism.  The  differential  pulse polarographic peak was adequately well-resolved, reproducible and  linear  dependent  with  the  zinecard  concentration.  For quantification  the  calibration  plot   for  zinecard  concentrations ranging  between  1.0×10-5mol  dm-3 to  1.0×10-8mol  dm-3 at pH  4.0  was  selected.  The  proposed  differential  pulse polarographic  method  was  successfully  applied  to  the determination  of  zinecard  in  pharmaceutical  formulations  and urine samples.

Key words:  Zinecard,    DPP,    pharmaceutical    formulations    and urine samples.


Full Text:



Bjelogrlic S.K., RadicJ., Radulovic S., Jokanovic and M., Jovic V., 2007, Effects of dexrazo-xane and amifostine on evolution of Doxorubicin cardiomyopathy in vivo. Exp Biol Med. 232(11):1414-24.

Cvetković R.S., and Scott L.J., Dexrazoxane 2005, A review of its use for cardioprotection during anthracycline chemotherapy. Drugs. 65(7):1005-24.

Hasinoff B.B., and Semin Oncol. 1998, Chemistry of dexrazoxane and analogues 25, 3-9.

Hasinoff, B.B., 1994b, Pharmacodynamics of the hydrolysis-activation of the cardioprotective agent (1)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane. J. Pharm. Sci. 83, 64 – 67.

Hasinoff, BB., 1994a, An HPLC and spectrophotometric study of the hydrolysis of ICRF-187 (dexrazoxane, (1)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane) and its one-ring opened intermediates. Int. J. Pharm. 107:67–76.

Kane Robert C., McGuinn, W., David, Dagher., Ramzi Justice., Robert Pazdur., and Richard 2008. "Dexrazoxane (Totect™): FDA Review and Approval for the Treatment of Accidental Extravasation Following Intravenous Anthracycline Chemo-therapy". The Oncologist 13 (4): 445–50.

Lipshultz S.E., Rifai N., Dalton VM., 2004. "The effect of dexrazoxane on myocardial injury in doxorubicintreated children with acute lymphoblastic leukemia". N. Engl. J. Med.351, 145–53.

McEvoy G., 2005. AHFS Drug Information. Bethesda, MD: American Society of Health-System Pharmacists.

Wiseman L.R., and Spencer C.M., 1998, Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapyb . Drugs, 56(3), 385-403.

DOI: http://dx.doi.org/10.14499/indonesianjpharm0iss0pp147-155


  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Indonesian J Pharm indexed by:


analytics View My Stats